<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624737</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200055</org_study_id>
    <nct_id>NCT04624737</nct_id>
  </id_info>
  <brief_title>Intelligent Evaluation of Diabetic Retinopathy</brief_title>
  <acronym>EviRed</acronym>
  <official_title>Intelligent Evaluation of Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief Summary: The main objective of EviRed project is to develop and validate a system&#xD;
      assisting the ophthalmologist by improving prediction of evolution, and decision making&#xD;
      during diabetic retinopathy (DR) follow-up. It will replace the current classification of&#xD;
      diabetic retinopathy (DR) which provides an insufficient prediction precision. It will use&#xD;
      modern available fundus imaging devices and artificial intelligence (AI) to properly&#xD;
      integrate the amount of data they provide with other medical data of the patient. A cohort of&#xD;
      5000 diabetic patients will be recruited and followed for an average of 2 years in order to&#xD;
      collect data to train and validate the new prediction system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cohort of 5,000 diabetic patients with different stages of DR will be recruited and&#xD;
      followed for an average of 2 years. Each year, general data as well as ophthalmological data&#xD;
      will be collected. Retinal images and videos of both eyes will be acquired using different&#xD;
      imaging modalities including ultrawidefield photography, OCT and OCT angiography. The EviRed&#xD;
      cohort will be split in two groups: one group of 1,000 patients (validation cohort) will be&#xD;
      randomly selected during the inclusion period by unbalanced draw to be representative of the&#xD;
      general diabetic population. Their data will be used for the validation of the algorithms.&#xD;
      The data of the remaining 4,000 patients (training cohort) will be used to train the&#xD;
      algorithms. The main objective will be the validation of the prognostic tool and evaluate how&#xD;
      accurately the algorithm can predict progression to severe retinopathy in the following year.&#xD;
      Secondary objectives will be to evaluate how accurately the algorithm can assess DR severity&#xD;
      and individual components of DR complications as well as to compare prediction by algorithm&#xD;
      to that made by ophthalmologists based on the current DR classification&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">January 21, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 21, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression to severe retinopathy</measure>
    <time_frame>month 12</time_frame>
    <description>Progression towards severe diabetic retinopathy form.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Algorithm performance</measure>
    <time_frame>3 years</time_frame>
    <description>Algorithms will be evaluated by comparing the algorithm performance to automatically assess diabetic retinopathy severity as well as individual components of severe retinopathy against the same grading made by human graders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of algorithms prediction to human prediction.</measure>
    <time_frame>3 years</time_frame>
    <description>at each patient's visit of the validation cohort, ophthalmologists will evaluate the risk of DR progression based on the current DR classification and their clinical experience. The risk of DR will be expressed by the clinician as a continuous variable (its estimated probability of progression) or as a semi-quantitative variable. Performance of the human prediction will be compared to the algorithm using sensitivity, specificity and AUC.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study will concern patients with both type1 and type 2 diabetes mellitus, as well as&#xD;
        other forms of more rare diabetes mellitus. As the goal of the study is to train the&#xD;
        algorithms to predict the progression of DR at one year, we'll exclude diabetic patients&#xD;
        with no risk of progression such as patients with type 1 diabetes and diabetes duration&#xD;
        less than 10 years. This cohort of patients will include 10% of patients without DR of with&#xD;
        minimal non proliferative DR, and 90% of patients with moderate non proliferative DR or&#xD;
        more severe. All DR stages will be represented with, however, a greater proportion of&#xD;
        patients with moderate or severe stages of DR which are at higher risk of DR progression&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with type 1 or type 2 diabetes or other,&#xD;
&#xD;
          -  aged 18 years or more,&#xD;
&#xD;
          -  diabetes duration greater than 10 years for type 1 diabetes,&#xD;
&#xD;
          -  no previous vitrectomy,&#xD;
&#xD;
          -  patient affiliated to social security,&#xD;
&#xD;
          -  women of childbearing potential who are unwilling or unable to use a method to avoid&#xD;
             pregnancy; women who are pregnant or breastfeeding can be included in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ungradable fundus photography or OCT/OCTA imaging,&#xD;
&#xD;
          -  previous treatment with vitrectomy,&#xD;
&#xD;
          -  participant is unable or unwilling to comply with study procedures (including foreign&#xD;
             language speakers who are not assisted by a native language speaker),&#xD;
&#xD;
          -  vulnerable participants (minors, legally detained),&#xD;
&#xD;
          -  patients under legal protection (guardianship),&#xD;
&#xD;
          -  prisoners or subjects who are involuntarily incarcerated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ramin TADAYONI, MD</last_name>
    <phone>+33 6 08 56 33 47</phone>
    <email>ramin.tadayoni@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascale MASSIN, MD</last_name>
    <phone>+ 33 6 81 34 63 53</phone>
    <email>pascale.massin@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Giocanti, MD</last_name>
      <phone>+33148957100</phone>
      <email>audrey.giocanti@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Francois KOROBELNIK, MD</last_name>
      <phone>+33557821217</phone>
      <email>jean-francois.korobelnik@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Cochener, MD</last_name>
      <phone>+33298223440</phone>
      <email>beatrice.cochener@ophtalmologie-chu29.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chic Creteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Souied, MD</last_name>
      <phone>+33145175225</phone>
      <email>Eric.Souied@chicreteil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Creuzot, MD</last_name>
      <phone>0380295173</phone>
      <email>catherine.creuzot-garcher@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Lyon Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent KODIJKIAN, MD</last_name>
      <phone>+33426109321</phone>
      <email>laurent.kodjikian@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramin TADAYONI, MD</last_name>
      <phone>+33 6 08 56 33 47</phone>
      <email>ramin.tadayoni@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Broca / Mutuelle Generale</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PASCALE MASSIN, MD</last_name>
      <phone>+ 33 6 81 34 63 53</phone>
      <email>pascale.massin1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Braham BODAGHI, MD</last_name>
      <phone>+33142163231</phone>
      <email>bahram.bodaghi@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital des 15-20</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Paques, MD</last_name>
      <phone>+33140021520</phone>
      <email>michel.paques@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic retinopathy. .</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Artificial intelligence.</keyword>
  <keyword>Deep learning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

